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ABSTRACT: 
 
While revisiting biologically active natural peptides, the importance of the tryptophan residue became 
clear. In this article, the incorporation of this amino acid, brominated at different positions of the indole 
ring, into cyclic peptides was successfully achieved. These products demonstrated improved properties in 
terms of passive diffusion, permeability across membranes, biostability in human serum and cytotoxicity. 
Moreover, these brominated tryptophans at positions 5, 6 or 7 proved to be compatible as building blocks 
to prepare bicyclic stapled peptides by performing on-resin Suzuki-Miyaura cross-coupling reactions. 
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INTRODUCTION: 
 
The relevance of the amino acid tryptophan is widely known in the field of natural products, as this 
particular building block represents an important biosynthetic precursor for some bioactive compounds 
such as alkaloids1. 
 
A common feature of membrane-spanning proteins is their preference for aromatic amino acids, namely 
tyrosine or tryptophan2,3. Aromatic, as well as charged, amino acids may act as an anchor for these 
proteins while they also participate in interfacial interactions4. The indole ring of tryptophan can display 
π-cation interactions, which are known to be of high importance in biological systems and are of 
increasing interest in medicinal chemistry. These interactions are present in 65% of the protein interfaces5 
and are considered to be real driving forces in biological processes. Stability and folding of proteins6 along 
with specific drug-receptor interactions7 have been related to π-cation interactions. 
 
The presence of tryptophan in peptides and proteins is crucial for their biological activity despite their low 
natural abundance (less than 1% of amino acids)8. During the beginning of the 21st century, novel 
substitution patterns within tryptophan were discovered, thus providing structures that are not directly 
accessible for ribosomes, and including post-translational modifications. Ribosomally synthesized and 
post-translationally modified peptides (RiPPs) comprise constrained peptides with improved 
pharmacological properties such as higher stability, functionality and target recognition9. Those 
biologically active peptides are formed through a rich variety of post-translational modification 
chemistries, some in the field of tryptophan derivatization. The gamma position of tryptophan can, for 
example, be isoprenylated in bacteria with a farnesyl moiety or geranyl group, yielding a tricyclic proline-
like core in the latter case10. Another unusual modification is produced in bacteria with metalloenzymes 
able to crosslink Lys and Trp side chains and form macrocyclic peptides11. Within RiPPs, lanthipeptides, 
for instance, constitute an abundant family, some of which possess antimicrobial activities. Of note and 
through biocatalysis, a unique 5-ClTrp moiety is present in a clinical candidate, being responsible for its 
increased antimicrobial bioactivity12.  
 
Tryptophan’s scarce presence in proteins might be the ideal opportunity for selective derivatization, 
although it can also suffer from a poor accessibility when aiming at conjugation. For this latter strategy, 
tryptophan can be introduced by recombinant engineering. Trp can be abolished in a living organism via 
a surrogate noncanonical amino acid named L-β-(thieno[3,2-b]pyrrolyl)alanine ([3,2]Tpa)13. This 
modification was later implemented in bioactive peptides by genetic code engineering14. The specific 
reactivity of this amino acid is an important challenge to overcome when addressing protein 
bioconjugation. Trp side- chain labeling can be reached using malonaldehydes in harsh reaction 
conditions, as well as with metallocarbenoids15. A relevant example was described by Hansen et al.16 
performing chemo- and regioselective ethynylation of Trp-containing proteins. In addition to the 
outstanding selectivity obtained, the alkyne produced can serve as a handle to undergo click chemistry or 
the Pd-catalyzed Sonogashira reaction. Owing to the great interest in tryptophan bioconjugation and the 
relevant concerns of the current methods, novel strategies continuously appear. Interestingly, a transition 
metal-free bioconjugation has recently been described17. 
 
Natural cyclizations involving the Trp side chain mainly take place through 5-membered ring formation. 
For example, the Savige-Fontana tryptathionylation, gives way to a rigid bicyclic peptide cross-link utilizing 
Trp and Cys side chains18. Iodine-mediated Cys deprotection and formation of the Trp-Cys thioether bridge 
provided an analogous result19. Nevertheless, we developed an alternative strategy to form a 6-
membered ring. Given the broad interest in Trp-based chemistry, new synthetic strategies have been 
applied for the derivatization of the indole ring of tryptophan. Among all possible derivatization products, 
the halotryptophan motif is especially relevant due to its presence in natural bioactive compounds20,21. 
Introduction of halogens at different positions of the indole ring of tryptophan opens a gateway to new 
peptides with interesting properties. Moreover, access to these building blocks is realized by 
biotransformation of readily available starting materials.22 The potential fine-tuning of some properties 
such as the membrane permeability, biostability in human serum or fluorescence is highly significant in 
the future application of these building blocks. In addition to halogens, other interesting groups such as a 
cyano, azido or hydroxyl function are also quite relevant, and all of them can be obtained from the same 
precursor, namely a boronated Trp23.  
Introduction of some Trp analogues in catalytic proteins has proved to be advantageous24. In this context, 
Trp has, for example, demonstrated its involvement in the catalysis of ligninolytic peroxidases25. 
 
Of relevance to this work, halogenated peptides, as well as borylated ones, can also be used as synthetic 
precursors for Suzuki-Miyaura reactions. Taking advantage of the previously established methodology for 
on-resin Suzuki-Miyaura cross-coupling reactions26,22, bicyclic tryptophan-stapled peptides can be 
prepared as privileged peptide scaffolds involved in membrane transport.   
METHODS: 
 
Protected amino acids were supplied by Iris Biotech (Marktredwitz, Germany). Wang® resin was obtained 
from PCAS BioMatrix Inc. (Quebec, Canada). DIEA, DIPCDI and ninhydrin were purchased from Fluka 
Chemika (Buchs, Switzerland) and HOAt from GL Biochem Shangai Ltd. (Shangai, China). Solvents for SPPS, 
such as DMF and DCM, were purchased from SDS (Barcelona, Spain) and trifluoroacetic acid (TFA) from 
Scharlau (Barcelona, Spain). Other chemical reagents were acquired from Aldrich (Milwaukee, WI) with 
the highest commercially available purity. Syringes of 20 ml for SPPS and Eppendorf tubes were provided 
by Scharlau and Falcon tubes by Deltalab. PAMPA plates and system solution were supplied by pION 
(Woburn, MA USA), and porcine polar brain lipid extract (PBLEP) by Avantis Polar Lipids (Alabaster, AL). 
The basic instruments used were a lyophilizer (Virtis, Frezzmobile 25 EL), oven (Selecta, Digitronic), vortex 
[Merck Eurolab, MELB1719 (EU)], magnetic stirrer (IKA, RCT basic), centrifuge (Eppendorf, 5415R), 
GUTBOX ™ (pION Aqueous Boundary Layer Thickness @ Double-Sink™), pipettes (Gilson, Pipetman P2, 
P20, P200, P1000) and Shimadzu UV-2501 PC UV–VIS spectrophotometer.  
 
Characterization of the peptides and purity assessment 
HPLC-analytical scale 
HPLC analyses were performed on a Waters Alliance 2695 with an automated injector and a photodiode 
array detector 2998 Waters (Waters, Milford, MA) using a SunFireTM C18 column, 3.5 μm, 4.6x100 mm. 
EmpowerPro 2 software was used to process the data. Detection was performed at 220 nm. The analyses 
were carried out with a linear gradient of CH3CN (0.036% TFA) in H2O (0.045% TFA) over 8 min at a flow 
rate of 1 ml/min. High performance liquid chromatography purification was performed in a Waters system 
with 2545 binary gradient module, a 2767 manager collector, and a 2998 photodiode array detector with 
MassLynx 4.1 software. The column used was a Sunfire™ C18, 3.5 μm, 10 × 150 mm, 100 Å from Waters. 
The solvents were prepared as CH3CN (0.1% TFA) and H2O (0.1% TFA). The flow rate was 10 ml/min. 
Analytical HPLC analyses were performed to validate the correct purification of the peptide. Purity and 
identity was assessed by analytical UPLC-MS. Different gradients were explored to assess separation of 
the peak corresponding to the product from the impurities. 
 
UPLC 
UPLC analyses were performed on a Waters Acquity with an automated injector and a photodiode array 
detector Waters (Waters, Milford, MA) using a BEH C18 column, 1.7 µm, 2.1x50 mm. Data was processed 
with an EmpowerPro 3 software. Detection was performed at 220 nm. The analyses were carried out with 
linear gradients CH3CN, UPLC grade, (0.036% TFA) in H2O (0.045% TFA) over 2 min at a flow rate of 0.61 
ml/min.  
 
UPLC-ESI-MS 
UPLC-MS analyses were performed on a Waters Acquity with an automated injector and a photodiode 
array detector Waters (Waters, Milford, MA) coupled to an electrospray ion source ESI-MS Micromass ZQ. 
A BEH C18 column, 1.7 µm, 2.1x50 mm was used. Data were processed with Masslynx 4.1 software. The 
instrument was operated in the positive ESI (+) ion mode. Detection was performed at 220 nm and the 
analyses were carried out with linear gradients CH3CN, UPLC grade, (0.07% formic acid) in H2O (0.1% 
formic acid) over 2 min at a flow rate of 0.61 ml/min. Samples were introduced, in a volume (1-100 μL) 
whose absorbance unit was between 0.2-0.4, into the mass spectrometer ion source directly through an 
UPLC autosampler. 
 
 
MALDI-TOF MS 
Mass spectrometry characterization of some peptides was carried out using a MALDI-TOF Applied 
Biosystem 4700. 1 μL of the peptide in a solution with a concentration around 1 mg/mL was mixed with 1 
μL of α-cyano-4-hydroxycinnamic acid (ACH) matrix, and then seeded on the MALDI plate and air-dried. 
For the matrix, 10 mg/mL solution of ACH was prepared in CH3CN/H2O 1:1 (v/v) with 0.1% TFA. 
 
LTQ-FT MS 
Some of the peptides were analysed using a high-resolution mass spectrometer to obtain their exact mass. 
Samples were dissolved in 200 µL of H2O:CH3CN and diluted in H2O:CH3CN 1% formic acid for MS analysis. 
The analysis was performed in a LTQ-FT Ultra (Thermo Scientific) and the samples were introduced by 
automated nanoelectrospray. A NanoMate (Advion BioScience, Ithaca, NY, USA) infused the samples 
through the ESI Chip, which consists of 400 nozzles in a 20x20 array. Spray voltage was 1.7 kV and delivery 
pressure was 0.3 psi. MS conditions were: NanoESI, positive ionization, capillary temperature 200 ºC, tube 
lens 119 V, ion spray voltage 2 kV and m/z 100-2000 amu.  
 
NMR 
1H NMR and 13C NMR spectra were recorded on a Bruker Avance DRX 250 console and a Bruker Avance II 
500 console at 250 or 63 MHz and 500 or 126 MHz, respectively. The deuterated solvent is mentioned for 
each product and spectrum. Chemical shifts (δ) are presented in parts per million (ppm), while coupling 
constants (J) are given in Hertz (Hz).  
 
General method for the solid-phase peptide synthesis 
Solid-phase peptide syntheses were performed at different scales between 100 and 500 µmols. L-amino 
acids were used except for D-proline. Peptide elongations were carried out in 20-ml polypropylene 
syringes, each fitted with a polypropylene porous disk. Solvents and soluble reagents were removed by 
filtration. Washings between steps were performed with DMF (3x30 s) and DCM (3x30 s) using 10 ml of 
solvent/g resin each time. During couplings, the resin was stirred using an orbital shaker. 
 
Amino acid H-(XBr)Trp-OH x=5,6 or 7  
The halotryptophans were prepared according to a reported biotransformation method22 and obtained 
as HCl salts. Briefly, the indole substrate (2 mmol) and serine (1.25 equiv., 2.5 mmol) were suspended in 
100 ml buffer (100 mM potassium phosphate, adjusted to pH 7.8 using 10 M potassium hydroxide). The 
cell lysate (3 ml), obtained as described in Smith et al.13 was transferred to dialysis tubing and gently placed 
in the reaction mixture. The reaction was incubated at 37 °C while shaking at 180 rpm for 48 hours. The 
cellulose tubing was removed and washed with water. Unreacted indole was recovered by extraction with 
ethyl acetate (2 x 50 ml) and the aqueous phase was concentrated under reduced pressure to 
approximately 50 ml. The crude halotryptophans were purified by reverse-phase (RP) column 
chromatography with 97:3 and 0.5:99.5 methanol:water used as mobile phases. The reverse-phase 
column was packed in methanol and conditioned by passing 50 ml of 20 %, 40 %, 60 %, 80 % and 100 % 
water in methanol through the column sequentially, never allowing the column to run dry. A further 250 
ml water was passed through the column, after which the concentrated aqueous phase was loaded onto 
the column. 500 ml water was passed through the column to remove salts, serine, and pyridoxal 
phosphate (PLP). Halotryptophans were eluted by passing 250 ml methanol through the column, following 
which the solvent was removed under vacuum. The sample was then treated twice with 20 ml 0.1 M 
hydrochloric acid to convert the tryptophan to the hydrochloride salt, removing the solvent under 
reduced pressure. The salt was then dissolved in 50 - 100 ml water and lyophlised to obtain the purified 
L-halotryptophan as a colourless, pink, yellow, or tan powder. 
- Characterization of 5-bromotryptophan 
HPLC tR: 10.7 min; MS (ESI): [M+H, 79Br]+expected= 283; [M+H, 79Br]+found= 283, [M+H, 81Br]+expected= 285; [M+H, 
81Br]+found= 285; 1H NMR (300 MHz, D2O): δ 7.67 (1H, d, J = 1.8), 7.30 (1H, d, J = 8.7), 7.25 - 7.19 (2H, m), 
4.23 (1H, dd, J = 7.1, 5.5), 3.32 (1H, dd, J = 15.4, 5.4), 3.24 (1H, dd, 15.4, 7.2); 13C NMR (75 MHz, D2O): 
172.3, 135.2, 128.5, 126.8, 124.9, 120.8, 113.8, 112.3, 106.3, 55.6, 26.0. 
- Characterization of 6-bromotryptophan 
HPLC tR: 10.8 min; MS (ESI): [M+H, 79Br]+expected= 283; [M+H, 79Br]+found= 283, [M+H, 81Br]+expected= 285; [M+H, 
81Br]+found= 285; 1H NMR (300 MHz, D2O): δ 7.55 (1H, d, J = 1.7), 7.39 (1H, d, J = 8.5), 7.18 (1H, s), 7.15 (1H, 
dd, J = 8.5, 1.7), 4.24 (1H, dd, J = 7.0, 5.5), 3.35 (1H, dd, J = 15.4, 5.5), 3.27 (1H, dd, J = 15.4, 7.1); 13C NMR 
(75 MHz, D2O): ∂ 172.3, 137.3, 126.2, 125.8, 122.6, 119.8, 115.2, 114.8, 106.9, 53.6, 26.0. 
- Characterization of 7-bromotryptophan 
HPLC tR: 10.7 min; HRMS (ESI):  283.0077 calcd. for C11H1179BrN2O2; [M+H, 79Br]+found= 283.0057; 285.0057 
calcd. for C11H1181BrN2O2; [M+H, 81Br]+found= 285.0045. 1H NMR (300 MHz, D2O): δ 7.54 (1H, dd, J = 8.0, 0.8), 
7.36 (1H, dd, J = 7.6, 0.6), 7.26 (1H, s), 6.99 (1H, t, J = 7.8), 4.25 (1H, dd, J = 5.5, 7.1), 3.38 (1H, dd, J = 5.3, 
15.7), 3.29 (1H, dd, J = 7.0, 15.5); 13C NMR (75 MHz, D2O): ∂ 172.4, 135.1, 128.2, 126.2, 124.8, 121.0, 117.9, 
108.1, 104.8, 53.7, 26.2. 
 
Amino acid derivatization Fmoc-(XBr)Trp-OH x=5,6 or 7 
The Fmoc-protected building blocks were synthesized according to the following procedure: The 
corresponding bromotryptophan hydrochloride salt (500 mg, 1.57 mmol) was dissolved with Na2CO3 (1.2 
equiv., 1.89 mmol) in 10 ml H2O. To this was added a solution of Fmoc-OSu (1.1 equiv., 1.72 mmol) in 10 
ml dioxane. The reaction mixture was stirred overnight at room temperature. Reaction completion was 
checked by HPLC and the mixture was concentrated. The resulting aqueous phase was acidified with 1 N 
HCl (pH = 1) and extracted with DCM (4x 30 ml). The combined organic phase was washed with 1 N HCl, 
dried over MgSO4 and concentrated by rotary evaporation. The resultant crude was triturated with a 
mixture of DCM/hexane and filtered over a glass frit. The obtained pink solid was further purified with 
flash column chromatography (DCM/MeOH/AcOH 97:2:1, for rref see individual compound) and 
concentrated to obtain white solids. 
- Characterization of Fmoc-5-bromotryptophan 
HPLC tR: 18.9 min; TLC rref: 0.19 (DCM/MeOH/AcOH 97:2:1); HRMS (ESI): 529.0556 calcd. for 
C26H2081BrN2O4NaHp+; [M+H+]found=529.0552 ; 1H-NMR (500 MHz, DMSO-d6): δH 12.65 (1H, br s), 11.06 (1H, 
s), 7.87 (2H, d, J= 7.7 Hz), 7.75 (1H, d, J= 1.3 Hz), 7.70 (1H, d, J= 8.1 Hz), 7.63 (2H, dd, J= 15.6 Hz, 7.5 Hz), 
7.39 (2H, q, J= 7.1 Hz), 7.22-7.32 (4H, M), 7.17 (1H, dd, J= 8.5 Hz, 1.7 Hz), 4.14-4.22 (4H, M), 3.15 (2H, dd, 
J= 14.5 Hz, 4.6 Hz), 2.99 (2H, dd, J= 14.5 Hz, 9.8 Hz); Yield: 561 mg (71%) 
- Characterization of Fmoc-6-bromotryptophan 
HPLC tR: 18.9 min; TLC rref: 0.16 (DCM/MeOH/AcOH 97:2:1); HRMS (ESI): 529.0556 calcd. for 
C26H2081BrN2O4NaHp+; [M+H+]found= 529.0579; 1H-NMR (500 MHz, DMSO-d6): δH 12.66 (1H, br s), 10.98 (1H, 
s), 7.87 (2H, d, J= 7.5 Hz), 7.62-66 (3H, M), 7.51 (2H, M), 7.37-41 (2H, M), 7.27 (2H, M), 7.19 (1H, d, J= 2.3 
Hz),7.09 (1H, dd, J= 8.3 Hz, 1.4 Hz), 4.15-4.22 (4H, M), 3.16 (1H, dd, J= 14.5 Hz, 4.5 Hz), 2.99 (1H, dd, J= 
14.5 Hz, 9.8 Hz); Yield: 589 mg (75%) 
- Characterization of Fmoc-7-bromotryptophan 
HPLC tR: 19.3 min; TLC rref: 0.22 (DCM/MeOH/AcOH 97:2:1); HRMS (ESI): 529.0556 calcd. for 
C26H2081BrN2O4NaHp+; [M+H+]found= 529.0511; 1H-NMR (500 MHz, DMSO-d6): δH 12.71 (1H, br s), 11.09 (1H, 
s), 7.86 (2H, d, J= 7.5 Hz), 7.70 (1H, d, J= 8.1 Hz), 7.64 (1H, d, J= 7.5 Hz), 7.61 (1H, d, J= 7.5 Hz), 7.58 (1H, d, 
J= 7.9 Hz), 7.39 (2H, m),7.24-7.31 (4H, M), 6.93 (1H, t, J= 7.7 Hz), 4.19-4.24 (2H, M), 4.17 (2H, m), 3.19 (1H, 
dd, J= 14.5 Hz, 4.3 Hz), 3.19 (1H, dd, J= 14.5 Hz, 10.4 Hz); Yield: 592 mg (75%) 
 
Amino acid derivatization pNZ-(XBr)Trp-OH x=5,6 or 7 
The derivatized amino acid was prepared from H-(XBr)Trp-OH. p-Nitrobenzyl chloroformate (1 equiv.) was 
dissolved in dioxane (3 ml). Sodium azide (1.2 equiv.), previously dissolved in H2O (2 ml), was added to 
this solution. This mixture was vigorously stirred at room temperature for 3 h. The amino acid, dissolved 
in dioxane (16 ml) and 2% aq. NaHCO3 (16 ml), was then introduced dropwise. The mixture was allowed 
to react for 24 h at room temperature. The pH was kept at 9-10 and readjusted when needed. Completion 
of the reaction was monitored by thin layer chromatography (TLC).  
The crude product was separated in H2O/methyl-tert-butyl ether (MTBE) 1:1 (100 ml), and the aqueous 
phase was extracted with MTBE (2x50 ml). The pH was adjusted to 4 with aqueous HCl 12 N. The products 
precipitated as yellow pale solids which were finally filtered, washed, resuspended in H2O and lyophilized. 
 
Cleavage conditions  
Peptides were cleaved from the CTC resin using a mixture of 2% TFA in DCM (6x1 min) and from the Wang 
resin with 99:0.5:0.5 TFA/H2O/TIS. The compounds were then filtrated and washed with DCM. After 
evaporating under vacuum, they were dissolved in CH3CN:H2O and lyophilized. 
 
Head-to-tail cyclization in solution 
Cyclic peptides were prepared by treatment of the linear precursors with PyBOP (2 equiv.), HOAt (1 
equiv.), DIEA (6 equiv.) in DCM/1% DMF (final concentration 1 mM) at room temperature for 24-48 h. A 
final purification step by semipreparative HPLC on a C18 column was required to obtain the pure cyclic 
peptides. 
 
Characterization of the final peptides: 
cyclo(Lys-(5&)Trp-Lys-(5&)Trp-D-Pro) 
In the manuscript, we follow for brevity the nomenclature described in Spengler et al.27 
The peptide was prepared using the standard methodology of García-Pindado et al.11 pNZ-(5Br)Trp-OH 
and Fmoc-(5Br)Trp-OH were used as the second and fourth amino acid, respectively. The synthesis was 
performed on solid-phase using Fmoc/tBu chemistry. Miyaura borylation was carried out on-resin at the 
tripeptide level to form the boronic acid of the tryptophan derivative. Once the pentapeptide was 
obtained, the on-resin Suzuki reaction yielded the desired stapled peptide, bridged between the two 
tryptophan moieties. UPLC tR (G 0-100% CH3CN/H2O in 2 min): 1.45 min; UPLC-MS tR (G 0-100% CH3CN/H2O 
in 2 min): 1.68 min, [M+H+]expected= 710.90, [M+H+]found= 709.30, yield (synthesis+purification): 2% 
 
cyclo(Lys-(6&)Trp-Lys-(6&)Trp-D-Pro) 
The peptide was prepared using the standard methodology of García-Pindado et al.11 pNZ-(6Br)Trp-OH 
and Fmoc-(6Br)Trp-OH were used as the second and fourth amino acid, respectively. The synthesis was 
performed on solid-phase using Fmoc/tBu chemistry. Miyaura borylation was carried out on-resin at the 
tripeptide level to form the boronic acid of the tryptophan derivative. Once the pentapeptide was 
obtained, on-resin Suzuki reaction yielded the desired stapled peptide between the two tryptophans. 
UPLC tR (G 0-100% CH3CN/H2O in 2 min): 1.44 min; UPLC-MS tR (G 0-100% CH3CN/H2O in 2 min): 1.69 min, 
[M+H+]expected= 710.90, [M+H+]found= 709.80, (synthesis+purification): 5% 
 
cyclo(Lys-(7&)Trp-Lys-(7&)Trp-D-Pro) 
The peptide was prepared using the standard methodology of García-Pindado et al.11 pNZ-(7Br)Trp-OH 
and Fmoc-(7Br)Trp-OH were used as the second and fourth amino acids, respectively. The synthesis was 
performed on solid-phase using Fmoc/tBu chemistry. Miyaura borylation was carried out on-resin at the 
tripeptide level to form the boronic acid of the tryptophan derivative. Once the pentapeptide was 
obtained, on-resin Suzuki reaction yielded the desired stapled peptide between the two tryptophans.  
UPLC tR (G 0-100% CH3CN/H2O in 2 min): 1.75 min; UPLC-MS tR (G 0-100% CH3CN/H2O in 2 min): 1.75 min, 
[M+H+]expected= 710.90, [M+H+]found=709.70, yield (synthesis+purification): 3% 
 
cyclo(Lys-(5Br)Trp-Lys-(5Br)Trp-D-Pro) 
The peptide was prepared from D-Pro-2-chlorotrityl resin (1 equiv.= 0.58 mmol). Fmoc-(5Br)Trp-OH and 
Fmoc-Lys(Boc)-OH residues (3 equiv.) were attached using DIPCDI (2 equiv. for Trp and 3 equiv. for Lys) 
and HOAt (2 equiv. for Trp and 3 equiv. for Lys) as coupling agents. Cleavage of the sequence from the 
resin with TFA/DCM 2:98 provided the desired peptide. Subsequently, the general cyclization method was 
used. Boc removal was performed with TFA/DCM 1:1 solution. The mixture was stirred at room 
temperature for 2 h. The reaction was monitored by TLC (AcOEt/DCM 1:1) using the ninhydrin staining 
solution. The solvent was evaporated and the crude product was dissolved in H2O/ CH3CN 1:1 and 
lyophilized. UPLC tR (G 0-100% CH3CN/H2O in 2 min): 1.35 min; UPLC-MS tR (G 0-100% CH3CN/H2O in 2 
min): 1.42 min, [M+H+]expected= 884.69, [M+H+]found= 883.93, HRMS (ESI): 882.22962 calcd. for 
C39H50N9O5Br2; [M+H+]found= 882.22829; yield (synthesis + purification): 15% 
 
cyclo(Lys-(6Br)Trp-Lys-(6Br)Trp-D-Pro) 
This peptide was prepared from D-Pro-2-chlorotritl resin (1 equiv.= 0. 58 mmol). Fmoc-(6Br)Trp-OH and 
Fmoc-Lys(Boc)-OH residues (3 equiv.) were attached using DIPCDI (2 equiv. for Trp and 3 equiv. for Lys) 
and HOAt (2 equiv. for Trp and 3 equiv. for Lys) as coupling agents. Cleavage of the sequence with 
TFA/DCM 2:98 provided the desired peptide. The general cyclization method was used. Boc removal was 
performed with TFA/DCM 1:1 solution. The mixture was stirred at room temperature for 2 h. The reaction 
was monitored by TLC (AcOEt/DCM 1:1) using the ninhydrin staining solution. The solvent was evaporated 
and the crude product was dissolved in H2O/ CH3CN 1:1 and lyophilized. UPLC tR (G 0-100% CH3CN/H2O in 
2 min): 1.35 min; UPLC-MS tR (G 0-100% CH3CN/H2O in 2 min): 1.42 min, [M+H+]expected= 884.69, 
[M+H+]found= 883.99, HRMS (ESI): 882.22962 calcd. for C39H50N9O5Br2; [M+H+]found= 882.22969; yield 
(synthesis + purification): 15% 
 
cyclo(Lys-(7Br)Trp-Lys-(7Br)Trp-D-Pro) 
This peptide was prepared from D-Pro-2-chlorotrityl resin (1 equiv.= 0.58 mmol). Fmoc-(7Br)Trp-OH and 
Fmoc-Lys(Boc)-OH residues (3 equiv.) were attached using DIPCDI (2 equiv. for Trp and 3 equiv. for Lys) 
and HOAt (2 equiv. for Trp and 3 equiv. for Lys) as coupling agents. Cleavage of the sequence with 
TFA/DCM 2:98 provided the desired peptide. The general cyclization method was used. Boc removal was 
performed with TFA/DCM 1:1 solution. The mixture was stirred at room temperature for 2 h. The reaction 
was monitored by TLC (AcOEt/ DCM 1:1) using the ninhydrin staining solution. The solvent was evaporated 
and the crude product was dissolved in H2O/ CH3CN 1:1 and lyophilized. UPLC tR (G 0-100% CH3CN/H2O in 
2 min): 1.35 min; UPLC-MS tR (G 0-100% CH3CN/H2O in 2 min): 1.42 min, [M+H+]expected= 884.69, 
[M+H+]found= 883.99 , HRMS (ESI): 882.22962 calcd. for C39H50N9O5Br2; [M+H+]found= 882.22973; yield 
(synthesis + purification): 10% 
 
H-Lys-Trp-Lys-Trp-D-Pro-OH 
This peptide was prepared from D-Pro-2-chlorotrytil resin(1 equiv.= 0.58 mmol). Fmoc-Trp(Boc)-OH and 
Fmoc-Lys(Boc)-OH residues (3 equiv.) were attached using DIPCDI (3 equiv.) and HOAt (3 equiv.) as 
coupling agents. Cleavage of the sequence with TFA/DCM 95:5 provided the desired peptide. The mixture 
was evaporated and the crude product was dissolved in H2O/CH3CN 1:1 and lyophilized. UPLC tR (G 0-100% 
CH3CN/H2O in 2 min): 1.26 min; UPLC-MS tR (G 0-100% CH3CN/H2O in 2 min): 1.18 min, [M+H+]expected= 
744.90, [M+H+]found=744.10, HRMS (ESI): 744.41916 calcd. for C39H54N9O6; [M+H+]found=744.41898; yield 
(synthesis + purification): 60% 
 
cyclo(-Lys-Trp-Lys-Trp-D-Pro) 
This peptide was prepared from D-Pro-2-chlorotrytil resin (1 equiv.=mmol). Fmoc-Trp(Boc)-OH and Fmoc-
Lys(Boc)-OH residues (3 equiv.) were attached using DIPCDI (3 equiv.) and HOAt (3 equiv.) as coupling 
agents. Cleavage of the sequence with TFA/DCM 2:98 provided the desired peptide. Cyclization was 
performed with the general method followed by Boc removal with TFA/DCM 1:1 solution. The mixture 
was stirred at room temperature for 2 h. The reaction was monitored by TLC (AcOEt/DCM 1:1) using the 
ninhydrin staining solution. The solvent was evaporated and the crude product was dissolved in 
H2O/CH3CN 1:1 and lyophilized. UPLC tR (G 0-100% CH3CN/H2O in 2 min): 1.40 min; UPLC-MS tR (G 0-100% 
CH3CN/H2O in 2 min): 1.25 min, [M+H+]expected= 726.90, [M+H+]found=726.70, HRMS (ESI): 726.40859 calcd. 
for C39H52N9O5; [M+H+]found=726.40721; yield (synthesis + purification): 50% 
 
Parallel artificial membrane permeability assay (PAMPA) 
The PAMPA was used to measure the capacity of the peptides to cross membranes (such as the BBB) by 
passive diffusion. The effective permeability (Pe) of the compounds was determined at an initial 
concentration of 200 μM. The buffer solution was prepared from a concentrated commercial one, 
supplied by pION. Following the manufacturer’s instructions, system solution was adjusted to pH 7.4 using 
a 0.5 M NaOH solution. The peptides were dissolved in a mixture of buffer solution with 20% of 1-propanol 
used as co-solvent. The PAMPA sandwich was separated, and the donor well was filled with 195 μL of the 
compound solution of interest. A magnetic stirrer was placed in each well. The acceptor plate was put 
into the donor plate, ensuring that the underside of the membrane was in contact with the buffer. Then, 
4 μL of a mixture of phospholipids from a porcine polar brain extract (20 mg/ml) in dodecane 
(composition: 12.6% phosphatidylcholine (PC), 33.1% phosphatidylethanolamine (PE), 18.5% 
phosphatidylserine (PS), 4.1% phosphatidylinositol (PI), 0.8% phosphatidic acid and 30.9% of other 
compounds) was added to the filter of each well, followed by 200 μL of buffer solution. The plate was 
then covered and incubated at room temperature in a saturated humidity atmosphere for 4 h under 
orbital agitation at 25 μm of unstirred water layer (UWL). After this period, 165 μL/well of the solution 
from the donor and acceptor plates was transferred to the HPLC vials, except for the bicyclic compound, 
for which all the fractions were pooled. 100 μL of each linear, stapled and cyclic acceptor samples and 80 
μL of the bicyclic acceptor were injected into the HPLC apparatus. Transport was also confirmed by HPLC-
MS, which indicated that the integrity of the peptides was preserved. Regarding the donor and initial time 
samples, the linear compound was injected at 1 μL, the linear stapled peptide at 20 μL, the head-to-tail 
cyclic peptide at 10 μL, and the bicyclic peptide at 5 μL. The bicyclic acceptor was injected again at 1 and 
5 μL owing to the initial large absorbance obtained. 
The effective permeability after 4 h was calculated using equation 1 and the percentage of transport using 
equation 2. 
   
       [Equation 1] 
 
     [Equation 2] 
 
where t is time (h), CA(t) is the peptide concentration in the acceptor well at time t, and CD(t0) is the peptide 
concentration in the donor well at 0 h. Membrane retention (%R) was calculated from the difference 
between the total starting amount of peptide and the amount of peptide in the donor and acceptor wells 
at the end of the assay after 4 h. 
 
Stability in human serum 
Peptides at a final concentration of 3 mM were dissolved in HBSS and incubated at 37 ºC in the presence 
of 90% human serum for 24 h. At different incubation times (30 min, 1 h, 3 h, 6 h, 10 h, 12 h and 24 h), 50 
µL aliquots were treated with 200 µL of MeOH to precipitate serum proteins. After 30 min of 
centrifugation at 4 ºC, the supernatant was filtered and then analysed by HPLC to calculate the percentage 
of intact peptide in the sample. 
 
Cytotoxicity, XTT assay 
5000 HeLa cells were seeded in 96-well plates 24 h before starting the assay. After this period, cells with 
peptides at 200 µM and 500 µM in DMEM (1 mg/ml glucose) supplemented with 10% serum were 
incubated for 24 h. Then, medium with peptides was removed and the XTT reagent was added to a final 
concentration of 0.5 mg/ml. After a 3 h incubation, absorbance was measured at 475 nm. The same 
measure was performed after 6 h incubation. Cell viability was calculated by dividing the absorbance of 
wells treated with a given peptide by the absorbance of the untreated wells. The 6h incubation values 
were used for the calculations, since an absorbance higher than 2 is required to reach the plateau zone of 
fluorescence. Measurements were performed in triplicate. As a negative control, cells were incubated 
with medium and as positive control 1% of DMSO was introduced.  
 
RESULTS AND DISCUSSION: 
 
Encouraged by the notorious presence of halogenated tryptophans in natural products9,10, we aimed to 
study the effects of introducing this particular motif in a small size peptide sequence, containing five 
amino acids. 
 
Design of the peptides 
Within the current study, the core sequence was selected based on positive results obtained with a 
previously studied ‘Phe analogue’, i.e. H-Lys-Phe-Lys-Phe-D-Pro-OH. We selected a pentapeptide scaffold 
to carry out the cyclization since this amount of amino acids is a proper size to form the amide bond 
between the N- and C- termini rendering peptides with some rigidity. D-Proline was selected as C-terminal 
amino acid anchored to the resin, to favor cyclization in solution by inducing tight loops that generate the 
cyclization-prone conformation 28. Lysine incorporation provided good results in terms of passive diffusion 
permeability and poor membrane retention, as well as non-cytotoxicity in HeLa cells25. In this study, 
phenyalanines were substituted by tryptophans that were suitably decorated with bromine, to yield head-
to-tail cyclized and brominated peptides. Herein, the incorporation of Trp could positively influence 
peptide conformation and stability29. Moreover, the biaryl staple between two phenyalanines was 
extensively studied in our group and could be successfully replaced with a staple involving positions 5-5, 
6-6 or 7-7 of two tryptophans. It is also worth mentioning that some articles describe Trp-containing 
peptides with antimicrobial, and hence possibly membrane interfering, properties22,30.  
Head-to-tail cyclic pentapeptides displaying two tryptophans, brominated at the same position (5,5; 6,6 
or 7,7 of the indole ring) were synthesized using standard Fmoc/tBu solid-phase peptide synthesis. We 
decided to introduce two identically substituted bromotryptophans to evaluate the potential effect of the 
indole substitution. The selected core sequence was exactly the same for all the peptides, i.e. H-Lys-Trp-
Lys-Trp-D-Pro-OH. Cyclization, as well as incorporation of a D-amino acid may prevent proteolytic 
degradation of the peptidic scaffold, a common disadvantage of peptide therapeutics.  
 
  
 
FIGURE 1. Cyclic pentapeptides with (5,5), (6,6) and (7,7) bromotryptophans, named Monocyclic 
5Br,Monocyclic 6Br and Monocyclic 7Br, respectively.  
 
To determine the impact of bromine substitution, two control peptides were also prepared: cyclo(Lys-
Trp-Lys-Trp-D-Pro) and H-Lys-Trp-Lys-Trp-D-Pro-OH; a head-to-tail cyclized peptide and a linear version 
with non-brominated tryptophans. 
 
Furthermore, we carried out the synthesis of bicyclic peptides using the halogenated tryptophans as 
precursors to undergo Suzuki-Miyaura conversions in view of a Trp-Trp crosslink. 
 
 
        
 
Bicyclic 5,5                Bicyclic 6,6  Bicyclic 7,7 
 
FIGURE 2. Bicyclic pentapeptides with stapling between positions 5-5, 6-6 or 7-7 of tryptophan.  
 
Bicyclic peptides have demonstrated to be privileged scaffolds that present improved pharmacological 
properties and prominent activities towards relevant biological targets31. Using our previously developed 
methodology for the preparation of bicyclic biaryl-containing pentapeptides11, we decided to prepare 
bicyclic peptides stapled between two tryptophans, at positions 5-5, 6-6 and 7-7 of the indole rings, taking 
advantage of the Suzuki-Miyaura reaction.  
Briefly, the bicyclic peptides were prepared using Wang resin as solid support and a modified Fmoc/tBu 
strategy. At the tripeptide level, on-resin borylation was carried out using Trt as the temporary protecting 
group and pNZ as the permanent one. Once the tryptophan was borylated through a Miyaura borylation, 
Trt was removed and the peptide was elongated on the solid support. The pentapeptide was then 
subjected to an on-resin Suzuki reaction having Boc as temporary protecting group and pNZ as the 
permanent one. Cleavage of the stapled precursor was carried out providing the peptide with side chain 
protecting groups on both lysines. After performing the prepurification of the peptide and the head-to-
tail cyclization, removal of pNZ was performed in solution yielding the desired stapled bicyclic peptide 
(Figure 3). 
 
Furthermore, this new construct presents an interesting motif (i.e., two stapled tryptophans) that could 
be used when trying to target surface recognition, as was demonstrated for the biaryl feature11,12, due to 
the possible π-cation interactions with the tryptophan staple. 
 
 
FIGURE 3. General methodology to synthesize ‘Trp-Trp stapled’ peptides based on the general 
methodology described by García-Pindado et al.11 X=5,6,7 denotes the position of Br in the indole of Trp. 
‘&’ corresponds to the cyclized positions (5-5, 6-6 or 7-7) between the two tryptophans.  
Once the compounds were prepared, we aimed to evaluate their properties in terms of passive diffusion 
permeability, resistance towards proteases and cytotoxicity. 
 
Passive diffusion permeability 
Owing to the special interest in peptide-based CNS drugs, these compounds were studied by PAMPA 
(Parallel Artificial Membrane Permeability Assay). The assay allows unveiling the potential passive 
diffusion permeability of these compounds across a mimic of the blood-brain barrier (BBB). We tested the 
three bromine-containing cyclic peptides and the bicyclic ones together with the two controls, obtaining 
the following results (Table 1, Figure 4). Propranolol was used as positive control of the assay. 
Cyclization of the linear peptide gave way to an enhanced permeability, also when performed in 
conjunction with the introduction of bromine at any of the studied positions of the indole ring of 
tryptophan. 
Pe represents the permeability of the compounds across the artificial BBB, while T stands for the 
percentage of transport of the peptides in the assay. These parameters allow to understand whether the 
tested compound show a relevant permeability through passive diffusion. An effective permeability 
higher than 1·10-6 cm/s correlates with a good transport prediction in vivo32. 
Upon comparison of the four head-to-tail cyclic peptides we observed an enhanced permeability when 
incorporating 5Br-Trp and 6Br-Trp, while in case of 7Br-Trp the permeability was slightly lower. These 
results demonstrated that halogens can be incorporated in a peptide and, in selected cases, this improves 
passive diffusion permeability. This tendency was previously reported by Malakoutikhak et al.33 
Nonetheless, it is worth noting the significant differences in the transport depending on the halogen 
position at the tryptophans, thus implying subtle changes in the properties of the bromine-containing 
cyclic peptides.  
 
TABLE 1. Effective permeability and transport of the cyclic brominated peptides, bicyclic peptides, the 
cyclo(Lys-Trp-Lys-Trp-D-Pro) reference, and linear H-Lys-Trp-Lys-Trp-D-Pro-OH after 4 h assayed by 
PAMPA. 
 
Compound Pe(x106) cm/s T(%) (4 h) 
Monocyclic 5Br: cyclo(K(5Br)WK(5Br)Wp) 4.7 ± 0.4 8.9 ± 0.7 
Monocyclic 6Br: cyclo(K(6Br)WK(6Br)Wp) 4.6 ± 0.1 8.9 ± 0.2 
Monocyclic 7Br: cyclo(K(7Br)WK(7Br)Wp) 1.3 ± 0.6 2.6 ± 1.1 
Head-to-tail cyclic: cyclo(KWKWp) 2.7 ± 0.2 5.3 ± 0.2 
Linear: H-KWKWp-OH 0.1 ± 3·10-3 0.2 ± 10-2 
Bicyclic 5,5: cyclo(K(5&)WK(5&)Wp) 3.8 ± 1.9 7.4 ± 2.4 
Bicyclic 6,6:cyclo(K(6&)WK(6&)Wp) 3.7 ± 0.6 7.2 ± 1.0 
Bicyclic 7,7: cyclo(K(7&)WK(7&)Wp) 7.6 ± 1.0 13.7 ± 1.5  
 
  
 
FIGURE 4. Effective permeability and transport after 4h in PAMPA. A) Comparison of cyclo(KWKWp) with 
bicyclic peptides and B) Comparison of cyclo(KWKp) and linear H-KWKp-OH with the brominated peptides. 
In blue Pe(x106) cm/s and in purple T(%) (4h).  
The bicyclic peptides did show a different behavior in terms of permeability. While bicyclic 5,5 and 6,6 
displayed a slight lower value of permeability than the monocyclic versions; Bicyclic 7,7 demonstrated to 
have the highest permeability across the BBB. Therefore, we could not attribute the incorporation of the 
stapled constraint to an increase in the transport. The differences can arise from the constraint of the 
structures between the aromatic residues involved in the stapling.  
Regarding membrane retention, we did not observe a significant value for any of the head-to-tail cyclic 
versions. On the contrary, the linear control was mostly retained on the membrane. This result was not 
surprising since tryptophans as well as N- and C- termini are described to interact with membranes. 
Therefore, cyclization is suggested to be a tool to avoid high membrane retention due to the lack of the 
N- and C-termini free. However, this strategy could lead to lower transport of the final compounds owing 
to the lost of both polar groups. 
 
Cell viability assay 
We were especially concerned by the potential cytotoxicity of these peptides due to the presence of two 
bromines. Therefore, an XTT assay was performed at two different concentrations (200µM and 500µM) 
in HeLa cells. 
As shown in Figure 5, no cytotoxicity could be directly attributed to the presence of bromine incorporation 
since complete cell survival was detected for both Monocyclic 6Br and Monocyclic 7Br peptides. 
Nevertheless, a relevant cell death was observed at 500 µM for Cyclic 5Br peptide. Again, we observed a 
significantly different behavior of the bromine-containing peptides depending on the halogen 
substitution. Due to the obtained results, we discarded Monocyclic 5Br for the following studies. 
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FIGURE 5. Cell viability assay at a concentration of 500 µM of the peptides. 
 
The high cytotoxicity of the Monocyclic 5Br peptide was an unexpected result that could be attributed to 
the adopted conformation of the sequence. Depending on the brominated positions at the indole, the 
final peptide conformation can be significantly different. Computational studies on conformation 
distribution would be interesting in order to improve our knowledge about this result. It is also relevant 
to highlight that natural halogenation or hydroxylation of tryptophan occurs in both 5- and 6- positions. 
 
Protease resistance in human serum 
As previously mentioned, head-to-tail cyclization is a well-known strategy used to improve peptide 
biostability in human serum. After having prepared these compounds, it became interesting to determine 
which effect the incorporation of bromine shows in terms of protease resistance. Therefore, the peptides 
were incubated in human serum for 24 h and the different time-point aliquots were analyzed by HPLC to 
determine half-life times. We observed that all of the head-to-tail cyclized peptides, including the cyclic 
control, were stable for more than 3 h in human serum. Even though the incorporation of bromine could 
not be linked to increased serum stability, the insertion of bromotryptophan amino acids did not lead to 
a more rapid degradation of the cyclic peptide analogues. Here, the linear peptide was used as positive 
control of the assay, displaying a half-life close to 1 h. 
 
Earlier studies of our group26 demonstrated that the incorporation of an extra cyclization increases 
considerably the biostability in human serum. The published results demonstrated outstanding values of 
protease resistance, which can be quite beneficial. Nonetheless, owing to the minimum amount of the 
bicyclic peptides obtained, these were not subjected to stability assays. 
 
CONCLUSIONS 
This piece of work illustrates how the incorporation of bromotryptophan amino acids in cyclic peptides 
enables to improve passive diffusion permeability devoid of cytotoxicity, and presents an adequate 
resistance towards protease degradation. Not only can these compounds be of interest for biological 
purposes, but also the bromotryptophan motif can be used to prepare stapled bicyclic peptides, known 
as privileged scaffolds for recognition of protein surfaces.  
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